

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>		<i>Complete if Known</i>	
		Application Number	10/595,656
		Filing Date	January 3, 2007
		First Named Inventor	Peter Kempers
		Art Unit	1623
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	
		C 2903 PCT/US	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.C./	1	US-6,153,594	11-28-2000	Boerretzen et al.	
/L.C./	2	US-6,348,451	02-19-2002	Von Borstel Reid Warren et al.	
/L.C./	3	US-20020035086	03-21-2002	von Borstel et al.	
/L.C./	4	US-6,258,795	07-10-2001	von Borstel et al.	
/L.C./	5	US-6,274,563	08-14-2001	von Borstel et al.	
/L.C./	6	US-6,316,426	11-13-2001	von Borstel et al.	
/L.C./	7	US-5,470,638	11-28-1995	von Borstel et al.	
/L.C./	8	US-5,583,117	12-10-1996	von Borstel et al.	
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ^{5 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.C./	9	GB 1 297 398	11-22-1972	Takeda	
/L.C./	10	EP 0 450 102	10-09-1991	Yamasa Shoyu Kabushiki Kaisha	
/L.C./	11	WO 02/088159	11-07-2002	Rudy Susilo	
/L.C./	12	WO 89/03837	05-05-1989	Pro-Neuron, Inc.	
/L.C./	13	EP 0 339 075 (abstract) (equiv. to WO89/03837)	05-05-1989	Pro-Neuron, Inc.	
/L.C./	14	WO 03/57894	07-17-2003	Innovate Biotechnology S.R.I.	

Examiner Signature	/Lawrence Crane/	Date Considered	6/24/2008
--------------------	------------------	-----------------	-----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/595,656	
(Use as many sheets as necessary)			Filing Date	January 3, 2007	
Sheet	2	of	2	First Named Inventor	Peter Kempers
			Art Unit	1623	
			Examiner Name		
			Attorney Docket Number		C 2903 PCT/US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
/L.C./	15	Krauch et al., "Synthesis and behaviour of nucleoside surface-active derivatives in monolayers", COLLOIDS AND SURFACES, 1991, vol.57, pgs 383-391. XP-002317768			
/L.C./	16	Zinni et al., "Regioselective preparation of 2', 3'-di'O-acylribonucleosides carrying lipophilic acyl groups through a lipase-catalysed alcoholysis", BIOTECHNOLOGY LETTERS, 2002, vol.24, pgs 979-983. XP-002317769			
/L.C./	17	Yun et al., "Novel thymidine-based organogelators and their gelation behaviours", CHEM. COMMUN., 2003, pgs 254-255. XP-002317770			
/L.C./	18	Li et al., "Molecular Recognition Capabilities of a Nucleolipid Amphiphile (3',5'-Distearyl)-2'-Deoxythymidine to Adenosine at the Air/Water Interface and Langmuir-Blodgett Films Studied by Molecular Spectroscopy", LANGMUIR, 2000, 16, pgs 7701-7707. XP-002317771			
/L.C./	19	Moris et al., "A Useful and Versatile Procedure for the Acylation of Nucleosides through an Enzymatic Reaction", J. Org. Chem., 1993, vol.58, pgs 653-660. XP-002212949			
/L.C./	20	Hammel et al., "Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system", Chemistry and Physics of Lipids, 2003, 123, pgs 193-207. XP-002317773			
/L.C./	21	Huang et al., "Synthesis of Novel Nucleolipid Amphiphiles", Synthetic Communications, 1997, 27(4), pgs 681-690. XP009044059			
/L.C./	22	Parang et al., "Syntheses and biological evaluation of 5'-O-myristoyl derivatives of thymidine against human immunodeficiency virus", Antiviral Chemistry & Chemotherapy, 1997, 8(5), pgs 417-427. XP009044063			
/L.C./	23	Nishino et al., "Partial Protection of Carbohydrate Derivatives. Part 18, Simple, preparative procedure for 5'-O-Acylribonucleosides; Highly Regioselective O-Deacylation at 2' and 3' Positions of Fully Acylated Purine and Pyrimidine Ribonucleoside Through Sodium Methoxide - THF System", Tetrahedron, 1985, vol.41, pgs 5503-5506.			
/L.C./	24	Uemura et al., "Lipase-catalyzed Regioselective Acylation of Sugar Moieties of Nucleosides", Tetrahedron Letters, 1989, vol.30, pgs 3817-3818.			
/L.C./	25	Ozaki et al., "Enzyme Aided Regioselective Acylation of Nucleosides", Nucleosides & Nucleotides, 1995, 14(3-5), pgs 401-404.			
/L.C./	26	Ozaki et al., "Enzyme aided regio-selective acylation and dacylation of nucleosides", Oxford Univ. Press, 1993, pgs 53-54.			
/L.C./	27	Singh et al., "Manipulation of Enzyme Regioselectivity by Solvent Engineering: Enzymatic Synthesis of 5'-O-Acylribonucleosides", Tetrahedron Letters, 1994, vol.35, pgs 1353-1356.			
/L.C./	28	Riva et al., "Protease-Catalyzed Regioselective Esterification of Sugars and Related Compounds in Anhydrous Dimethylformamide", J.Am.Chem.Soc., 1988, 110, pgs 584-589.			
**	29	Cosmetics Directive (Die Kosmetik-Verordnung), Deutsches Institut fur Koerperpflege und Hygiene e.V., Annex 6, Part A and B			
/L.C./	30	Bradford, Marion M., "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Analytical Biochemistry, 1976, vol. 72, pgs 248-254.			

Examiner Signature	Date Considered /Lawrence Crane/ (03/24/2008)
--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

** Bibliographic data incomplete; no date of publication, publisher, etc.